Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer

Next Previous
X
Search
Trial Profile

A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms FRUTIGA
  • Sponsors Hutchison MediPharma; HUTCHMED

    • Most Recent Events

    • 09 Sep 2024 According to HUTCHMED media release, the data of this trial will be presented at the the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain.
    • 30 Aug 2024 According to a HUTCHMED media release, results from this Phase III pivotal registration trial of fruquintinib in 416 patients with metastatic CRC in China, were published in The Journal of the American Medical Association, JAMA.
    • 30 Aug 2024 According to a HUTCHMED media release, following an additional internal review of the current data package, in light of recent discussions with the National Medical Products Administration of China (NMPA), company has determined that the submission is unlikely to support an approval in China at this time.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top